UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity

Cellular signalling, 2014-09, Vol.26 (9), p.2016-2029

2014

Volltextzugriff (PDF)

Small molecule allosteric modulators of phosphodiesterase 4

Handbook of experimental pharmacology, 2011 (204), p.167

2011

Volltextzugriff (PDF)

Difamilast ointment in adult patients with atopic dermatitis: A phase 3 randomized, double-blind, vehicle-controlled trial

Journal of the American Academy of Dermatology, 2022-03, Vol.86 (3), p.607-614

2022

Volltextzugriff (PDF)

New quinoline-based PDE4 inhibitors through GSK-256066 fragment-based elaboration

Journal of molecular structure, 2024-01, Vol.1295, p.136719, Article 136719

2024

Volltextzugriff (PDF)

Roles of roflumilast, a selective phosphodiesterase 4 inhibitor, in airway diseases

Journal of thoracic disease, 2017-04, Vol.9 (4), p.1144-1154

Kawamatawong, Theerasuk

2017

Volltextzugriff (PDF)

Facile synthesis of carbon-11-labeled sEH/PDE4 dual inhibitors as new potential PET agents for imaging of sEH/PDE4 enzymes in neuroinflammation

Bioorganic & medicinal chemistry letters, 2019-07, Vol.29 (13), p.1654-1659

2019

Volltextzugriff (PDF)

The PDE4 Inhibitor Tanimilast Blunts Proinflammatory Dendritic Cell Activation by SARS-CoV-2 ssRNAs

Frontiers in immunology, 2022-01, Vol.12, p.797390-797390

2022

Volltextzugriff (PDF)

Urinary liver‐type fatty acid binding protein is a biomarker reflecting renal damage and the ameliorative effect of drugs at an early stage of histone‐induced acute kidney injury

Nephrology (Carlton, Vic.), 2024-03, Vol.29 (3), p.117-125

2024

Volltextzugriff (PDF)

Mapping binding sites for the PDE4D5 cAMP-specific phosphodiesterase to the N- and C-domains of beta-arrestin using spot-immobilized peptide arrays

Biochemical journal, 2007-05, Vol.404 (1), p.71-80

2007

Volltextzugriff (PDF)

Selective SUMO modification of cAMP-specific phosphodiesterase-4D5 (PDE4D5) regulates the functional consequences of phosphorylation by PKA and ERK

Biochemical journal, 2010-05, Vol.428 (1), p.55-65

2010

Volltextzugriff (PDF)

1,1-Diarylalkenes as anticancer agents: Dual inhibitors of tubulin polymerization and phosphodiesterase 4

Bioorganic & medicinal chemistry, 2011-11, Vol.19 (21), p.6356-6374

2011

Volltextzugriff (PDF)

PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia

Clinical lymphoma, myeloma and leukemia, 2016-08, Vol.16, p.S67-S73

2016

Volltextzugriff (PDF)

The cardioprotective role of small heat-shock protein 20

Biochemical Society transactions, 2014-04, Vol.42 (2), p.270-273

2014

Volltextzugriff (PDF)

PKA phosphorylation of the small heat-shock protein Hsp20 enhances its cardioprotective effects

Biochemical Society transactions, 2012-02, Vol.40 (1), p.210-214

2012

Volltextzugriff (PDF)

Design, synthesis and in vitro PDE4 inhibition activity of certain quinazolinone derivatives for treatment of asthma

Medicinal chemistry research, 2012-11, Vol.21 (11), p.3327-3335

2012

Volltextzugriff (PDF)

Inhibition of osteoclastogenesis by a phosphodiesterase 4 inhibitor XT-611 through synergistic action with endogenous prostaglandin E 2

Biochemical pharmacology, 2003-09, Vol.66 (5), p.801-807

2003

Volltextzugriff (PDF)

Rubinstein-Taybi syndrome: molecular findings and therapeutic approaches to improve cognitive dysfunction

Cellular and molecular life sciences : CMLS, 2006-08, Vol.63 (15), p.1725-1735

2006

Volltextzugriff (PDF)

Novel bronchodilators in the treatment of asthma and COPD

Expert opinion on therapeutic patents, 2002-01, Vol.12 (1), p.53-63

2002

Volltextzugriff (PDF)

A novel phosphodiesterase 4 inhibitor template

Expert opinion on therapeutic patents, 2003-06, Vol.13 (6), p.929-933

2003

Volltextzugriff (PDF)

In vitro PKA phosphorylation-mediated human PDE4A4 activation

FEBS letters, 2002-02, Vol.512 (1), p.205-208

2002

Volltextzugriff (PDF)

Can the anti‐inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?

British journal of pharmacology, 2008-10, Vol.155 (3), p.288-290

Giembycz, M A

2008

Volltextzugriff (PDF)

PDE4 Inhibitors: Profiling Hits through the Multitude of Structural Classes

International journal of molecular sciences, 2023-07, Vol.24 (14), p.11518

2023

Volltextzugriff (PDF)

Small-molecule allosteric activators of PDE4 long form cyclic AMP phosphodiesterases

Proceedings of the National Academy of Sciences - PNAS, 2019-07, Vol.116 (27), p.13320-13329

2019

Volltextzugriff (PDF)

Clinical Implication of Phosphodiesterase-4-Inhibition

International journal of molecular sciences, 2022-01, Vol.23 (3), p.1209

2022

Volltextzugriff (PDF)

Phosphodiesterase-4 Inhibition in Parkinson’s Disease: Molecular Insights and Therapeutic Potential

Cellular and molecular neurobiology, 2023-08, Vol.43 (6), p.2713-2741

2023

Volltextzugriff (PDF)

1 – 25 von 268

Suche als RSS-Feed

Aktive Filter

ThemaRats

ThemaScience & Technology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(261)
Mit Volltextzugriff
(234)

Publikationsform

Artikel
(264)
Buchkapitel
(4)

Sprache

Englisch
(268)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity

Small molecule allosteric modulators of phosphodiesterase 4

Difamilast ointment in adult patients with atopic dermatitis: A phase 3 randomized, double-blind, vehicle-controlled trial

New quinoline-based PDE4 inhibitors through GSK-256066 fragment-based elaboration

Roles of roflumilast, a selective phosphodiesterase 4 inhibitor, in airway diseases

Facile synthesis of carbon-11-labeled sEH/PDE4 dual inhibitors as new potential PET agents for imaging of sEH/PDE4 enzymes in neuroinflammation

The PDE4 Inhibitor Tanimilast Blunts Proinflammatory Dendritic Cell Activation by SARS-CoV-2 ssRNAs

Urinary liver‐type fatty acid binding protein is a biomarker reflecting renal damage and the ameliorative effect of drugs at an early stage of histone‐induced acute kidney injury

Mapping binding sites for the PDE4D5 cAMP-specific phosphodiesterase to the N- and C-domains of beta-arrestin using spot-immobilized peptide arrays

Selective SUMO modification of cAMP-specific phosphodiesterase-4D5 (PDE4D5) regulates the functional consequences of phosphorylation by PKA and ERK

1,1-Diarylalkenes as anticancer agents: Dual inhibitors of tubulin polymerization and phosphodiesterase 4

PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia

The cardioprotective role of small heat-shock protein 20

PKA phosphorylation of the small heat-shock protein Hsp20 enhances its cardioprotective effects

Design, synthesis and in vitro PDE4 inhibition activity of certain quinazolinone derivatives for treatment of asthma

Inhibition of osteoclastogenesis by a phosphodiesterase 4 inhibitor XT-611 through synergistic action with endogenous prostaglandin E 2

Rubinstein-Taybi syndrome: molecular findings and therapeutic approaches to improve cognitive dysfunction

Novel bronchodilators in the treatment of asthma and COPD

A novel phosphodiesterase 4 inhibitor template

In vitro PKA phosphorylation-mediated human PDE4A4 activation

Can the anti‐inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?

PDE4 Inhibitors: Profiling Hits through the Multitude of Structural Classes

Small-molecule allosteric activators of PDE4 long form cyclic AMP phosphodiesterases

Clinical Implication of Phosphodiesterase-4-Inhibition

Phosphodiesterase-4 Inhibition in Parkinson’s Disease: Molecular Insights and Therapeutic Potential

Aktive Filter

Suchergebnisse filtern